Innate Pharma S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPHA research report →
About the company
Innate Pharma S. A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies.
- CEO
- Jonathan E. Dickinson
- IPO
- 2019
- Employees
- 181
- HQ
- Marseille, FR
Price Chart
- Market Cap
- $169.03M
- P/E
- -3.03
- P/S
- 56.07
- P/B
- -7.01
- EV/EBITDA
- -2.69
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2058.02%
- Net Margin
- -1764.51%
- ROE
- 593.93%
- ROIC
- -155.52%
- Revenue
- $2.79M · -77.92%
- Net Income
- $-49,177,000 · 0.59%
- EPS
- $-0.53 · 13.11%
- Op Income
- $-53,425,000
- FCF YoY
- -379.07%
- 52W High
- $2.63
- 52W Low
- $1.17
- 50D MA
- $1.71
- 200D MA
- $1.75
- Beta
- 0.89
- Avg Volume
- 72.67K
Get TickerSpark's AI analysis on IPHA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IPHA coverage
Recent articles, reports, and earnings notes.
No research on IPHA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPHA report →Similar companies
Peers in the same neighborhood.